Eton Pharmaceuticals Secures U.S. Rights to LIBERVANT in $57.5M Milestone Deal

Key numbers

Deal value	$10M
Share of market cap	0.7%
Share of annual revenue	12.5%

Key highlights

• $10 million upfront license fee paid to Aquestive Therapeutics upon signing
• Potential for $47.5 million in additional regulatory and commercial milestones
• Exclusive 20-year supply agreement with automatic three-year extensions
• Target commercial launch set for April 2027 following anticipated FDA approval
• Mid-teens percentage royalties on annual net sales of the product

What Is the Deal?

Eton Pharmaceuticals finalized an exclusive license agreement with Aquestive Therapeutics on October 13, 2026. The transaction grants Eton the rights to commercialize LIBERVANT (diazepam) buccal film in the United States and its territories. Under the terms, Eton paid an initial $10.0 million license fee. The deal also includes a concurrent 20-year supply agreement, where Aquestive will serve as the exclusive manufacturer. This acquisition targets the treatment of acute seizure clusters in epilepsy patients, with a projected commercial availability in April 2027, contingent upon final U.S. Food and Drug Administration approval.

Deal Structure & Terms

• $10.0 million upfront cash payment completed upon signing
• $10.0 million milestone due on first U.S. commercial sale, potentially halved if pediatric approval is pending
• $2.5 million regulatory milestone linked to FDA approval for patients aged 6 to 11
• $35.0 million in tiered commercial milestones based on reaching annual net sales targets
• Ongoing royalty payments calculated at a mid-teens percentage of annual net sales

Strategic Rationale

The acquisition integrates a late-stage neurology asset into Eton's existing portfolio of treatments for rare diseases. LIBERVANT utilizes a proprietary buccal film technology, offering a portable alternative to traditional rectal and nasal seizure rescue therapies. Market research cited in the transaction indicates a 71% patient preference for film-based delivery over nasal sprays when efficacy is comparable. By leveraging its established commercial infrastructure for specialty dosage forms, Eton aims to capture a portion of a domestic market estimated at $450 million annually. This deal follows a series of recent acquisitions, including rights to ASN-001, IMPAVIDO, and Galzin.

Financial Context

Eton's $10 million upfront investment represents a strategic deployment of capital relative to its $1.52 billion market capitalization. The company has recently updated its full-year 2026 net revenue guidance to exceed $145 million, supported by an expected Adjusted EBITDA margin above 35%. While the LIBERVANT launch is slated for early 2027, the product carries Orphan Drug Designation and patent protection extending through 2038. This licensing agreement strengthens Eton's revenue diversification strategy, which has seen the company transition from divesting international rights of Increlex to acquiring multiple U.S.-focused specialty pharmacy assets.

Management commentary

“LIBERVANT marks an important expansion of our portfolio into neurology and represents a compelling opportunity to bring an orphan-designated, differentiated therapy to patients.”

Eton Pharmaceuticals, Inc. · financial snapshot

Share price	$53.33
Market cap	$1.5B
Revenue (annual)	$80M
P/E (TTM)	133.3×
1-month price change	-6.57%
Sector	HealthcareDrug Manufacturers - Specialty & Generic

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.